Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neuroblastoma 12Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Osteosarcoma 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 16Temozolomide 13Vincristine 10Irinotecan 8Melphalan 7Doxorubicin 7Topotecan 6Granulocyte Colony-Stimulating Factor 6Busulfan 6fludarabine 5cabozantinib 5Etoposide 5Drug Therapy 5liposomal doxorubicin 4Sirolimus 4Ifosfamide 4Filgrastim 4regorafenib 3pegfilgrastim 3irinotecan sucrosofate 3fludarabine phosphate 3Zoledronic Acid 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Cisplatin 3Bone Marrow Transplantation 3Albumin-Bound Paclitaxel 3pegylated granulocyte colony-stimulating factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma, Ewing × naxitamab × Clear all
NCT05968768 2025-04-10

To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

Institute of Mother and Child, Warsaw, Poland

Phase 2 Recruiting
24 enrolled
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡